Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paimrizumab plus anlotinib for recurrent or metastatic cervical cancer (Phase II)
ChiCTR2100049618Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Sep 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab and anlotinib in cervical cancer (mCC), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Recurrence and metastasis lesions response. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on ChiCTR2100049618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049618.